Filing Flows

Filing Flows › Intelligent Bio Solutions (INBS) › Q1 FY26

Intelligent Bio Solutions (INBS) Q1 FY26 earnings results (first quarter fiscal 2026)

10-Q filed Nov 12, 2025

Intelligent Bio Solutions (INBS) reported revenue of $1.1M for the first quarter fiscal 2026 (Q1 FY26), +11% from a year earlier and +32% from the quarter before. Operating margin was -269.8%, net loss $3.0M (269.4% of revenue).

Revenue$1.1M
Year over year+11%
Quarter over quarter+32%
Operating margin-269.8%
Net earnings−$3.0M

Intelligent Bio Solutions, Q1 FY26: revenue $1.1M (+11% year over year), operating margin -269.8%, net loss $3.0M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.

Q1 FY26AmountQ/QY/Y
Revenue$1.1M+32%+11%
Operating profit−$3.0M——
Net earnings−$3.0M——
Operating cash flow−$2.8M——

What changed

Revenue was $1.1M in Q1 FY26, up 11% year over year and up 32% from the previous quarter. Sales of Goods Cartidges was the largest line at 58% of revenue. Sales of Goods Cartidges added $192K year over year (up 43%), 169% of the total change. Other Sales declined 3%.

Gross margin was 46.6%, up 11.9 points from a year earlier. Operating costs exceeded revenue by $3.0M, an operating margin of -269.8%. Operating expenses grew 15% against revenue growth of 11%. The fastest-growing cost line was General & admin (+36%). The quarter ended with a net loss of $3.0M, narrower than the previous quarter's $3.1M loss. Minority interests bore $12K of it: to shareholders the quarter was a loss of $3.0M.

Operating cash flow was −$2.8M. Non-cash charges added back $258K of depreciation and amortization and $12K of share-based compensation. Capital expenditures of $70K exceeded it, leaving free cash flow of −$2.9M.

Questions

What was Intelligent Bio Solutions' revenue in the first quarter fiscal 2026?

Intelligent Bio Solutions (INBS) reported revenue of $1.1M for the first quarter fiscal 2026 (Q1 FY26), +11% from a year earlier and +32% from the quarter before.

Was Intelligent Bio Solutions profitable in the first quarter fiscal 2026?

Operating loss was $3.0M (-269.8% of revenue) and net loss $3.0M.

Open the interactive Sankey →

Source: Intelligent Bio Solutions 10-Q on SEC EDGAR.